Liquidia

Needham analyst Serge Belanger named Liquidia a top pick for 2025 with a Buy rating and $19 price target. The stock was also the analyst's top pick for 2024, and "disappointed" with a negative 2% performance mostly due to the mid-August setback when the FDA delayed approval by retroactively granting Tyvaso DPI a three year exclusivity dating to 2022, Needham points out. The firm says its "investment thesis is stronger now than a year ago." It has a "clear line of sight" for FDA approval of Yutrepia in both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by May 23. Yutrepia will launch into an opportunity that will have grown into a $2B market by mid-2025, on its way to over $3B-$4B by 2030, contends the firm.» Mehr auf thefly.com

The mean of analysts' price targets for Liquidia Technologies (LQDA) points to a 132.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.» Mehr auf zacks.com

The consensus price target hints at a 126.1% upside potential for Liquidia Technologies (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.» Mehr auf zacks.com